Dr Reddy’s, GRA terminate Avigan study on hospitalised Covid cases in Kuwait
January 27, 2021
× Dr Reddy’s Laboratories Ltd and Global Response Aid FZCO (GRA) on Wednesday announced the termination of an Avigan Trial Study conducted in Kuwait focussed on moderate to severe Covid patients in a hospital setting.
The hospitalised patient study was one of the studies in the overall clinical programme for Avigan, spanning the spectrum of asymptomatic to severe cases of Covid in both outpatient and in-patient settings. Avigan is a trademark of Fujifilm Toyama Chemical Co Ltd.
The Phase-III study, being conducted in an outpatient setting on patients with mild to moderate symptoms in North America by Dr Reddy’s, in partnership with Appili Therapuetics and Global Response Aid, shall continue.
Dr Reddy s Laboratories Ltd, Appili Therapeutics and Global Response Aid FZCO (GRA) on Tuesday announced that Dr Reddy s Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate COVID-19 adult patients. The application has been filed under Health Canada s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, Hyderabad-headquartered pharma major Dr Reddy s said in a statement. In September, the interim order was signed by Canada s Minister of Health to create a new authorisation pathway that will help expedite the authorisation of drugs and vaccines for COVID-19.
Dr Reddy s seeks approval from Health Canada for Favipiravir financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
Representational image.
Dr. Reddy s is working closely with Health Canada for an expedited review of the drug application, says Vinod Ramachandran, Vice President and General Manager, Dr. Reddy’s Laboratories Canada Inc
Dr Reddy s Laboratories Ltd, Canada-based Appili Therapeutics and Dubai-based Global Response Aid FZCO (GRA) on Tuesday said Dr Reddy s Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) Tablets for treating COVID-19 in the North American country.
The application was filed under Health Canada s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, a release from the city-based drug maker said.